PUBLISHER: The Business Research Company | PRODUCT CODE: 1710197

PUBLISHER: The Business Research Company | PRODUCT CODE: 1710197

Dengue Vaccine Global Market Report 2025

PUBLISHED: April 3, 2025

PAGES: 200 Pages

DELIVERY TIME: 2-10 business days

ADD TO COMPARE

SELECT AN OPTION

Description

A dengue vaccine is a biological preparation aimed at preventing dengue fever, a viral disease transmitted by mosquitoes and caused by the dengue virus (DENV). When exposed to the virus in the future, dengue vaccines help stimulate the body's immune system to recognize and combat the dengue virus.

The primary types of dengue vaccines include live attenuated vaccines, chimeric live attenuated vaccines, inactivated vaccines, subunit vaccines, and nucleic acid-based vaccines. Live attenuated vaccines utilize a weakened form of the virus to elicit an immune response, training the body to fight dengue without causing the illness. These vaccines undergo various phases of development, including phase I, phase II, and phase III trials, and treatments associated with dengue may involve diuretics, anti-allergics, blood thinners, among others. They can be administered through different routes, such as oral and parenteral, and are used by a variety of end users, including hospitals, clinics, government institutions, and non-governmental organizations.

The dengue vaccines market research report is one of a series of new reports from The Business Research Company that provides dengue vaccines market statistics, including dengue vaccines industry global market size, regional shares, competitors with a dengue vaccines market share, detailed dengue vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the dengue vaccines industry. This dengue vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dengue vaccine market size has grown rapidly in recent years. It will grow from $0.64 billion in 2024 to $0.72 billion in 2025 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to growing travel and urbanization, increasing demand for effective vaccines, increasing prevalence of foreign travel exposure, increasing healthcare services, and rising mass vaccinations.

The dengue vaccine market size is expected to see rapid growth in the next few years. It will grow to $1.14 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to the increasing incidence of dengue, increasing initiatives by several organizations, increasing clinical trials, and growing emphasis on multi-strain and tetravalent vaccine formulations. Major trends in the forecast period include increasing demand for preventative vaccines, advancements in vaccine technology, development of combination vaccines, rise in research and clinical trials for new vaccine candidates, and focus on improving vaccine efficacy and safety profiles.

The increasing number of dengue fever cases is anticipated to drive the growth of the dengue vaccine market in the coming years. Dengue fever is a viral infection transmitted by Aedes aegypti mosquitoes, leading to symptoms such as high fever, headaches, joint pain, and rashes. The rise in dengue cases can be attributed to factors such as climate change, urbanization, insufficient mosquito control, and the evolution of the virus. The dengue vaccine functions by activating the immune system to recognize and fight the dengue virus, reducing the severity of infections and lowering the risk of severe complications, which helps decrease the number of cases and hospitalizations. For example, in May 2024, the World Health Organization, based in Switzerland, reported that dengue cases in the Americas exceeded 7 million in April 2024, up from 4.6 million cases in 2023. Thus, the increasing incidence of dengue fever is propelling the growth of the dengue vaccine market.

Leading companies in the dengue vaccine market are focusing on developing advanced vaccine formulations, such as the dengue tetravalent vaccine, which enhances protection against all four dengue virus serotypes in a single vaccine. The dengue tetravalent vaccine provides immunity against the four dengue serotypes (DEN-1, DEN-2, DEN-3, and DEN-4), offering comprehensive protection against dengue fever. For instance, in December 2022, Takeda Pharmaceutical Company, a pharmaceutical firm based in Japan, received approval from the European Commission for the use of the QDENGA vaccine in individuals aged four years and older. This live-attenuated vaccine is used in several dengue-endemic countries to protect against the disease and utilizes weakened dengue serotype two viruses as a genetic basis for the other three serotypes. It is administered in two doses of 0.5 mL each, given at 0 and 3 months, targeting individuals from the age of four and older. A Phase 3 trial indicated that QDENGA has an efficacy of approximately 80.2% against dengue, with particularly favorable results in preventing hospitalizations. Its protection is expected to last around 4.5 years, which is longer than many other vaccines.

In February 2024, Takeda Pharmaceutical Company entered into a partnership with Biological E. Limited, a biotechnology and biopharmaceutical company based in India. This collaboration aims to expedite the production and accessibility of the QDENGA (TAK-003) dengue vaccine in endemic regions by increasing manufacturing capacity and providing multi-dose vials to support national immunization initiatives.

Major companies operating in the dengue vaccine market are Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Sun Pharmaceutical Industries Ltd., Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd.

Asia-Pacific was the largest region in the dengue vaccine market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengue vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dengue vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dengue vaccine market consists of revenues earned by entities by providing treatment such as chlorothiazide, chlorthalidone, hydrochlorothiazide, and fexofenadine. The market value includes the value of related goods sold by the service provider or included within the service offering. The dengue vaccine market also includes sales of diagnostic kits, combination vaccines, clinical trial products, and post-vaccination monitoring tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dengue Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dengue vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dengue vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dengue vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Live Attenuated Vaccine; Chimeric Live Attenuated Vaccine; Inactivated Vaccine; Subunit Vaccine; Nucleic Acid Based Vaccine
2) By Vaccine Phase: Phase I; Phase II; Phase III
3) By Treatment: Diuretic; Anti-Allergic; Blood Thinners; Other Treatments
4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
5) By End-User: Hospitals; Clinics; Government Institutes; Non-Governmental Organizations; Other End-Users
Subsegments:
1) By Live Attenuated Vaccine: Single Strain; Multi-Strain
2) By Chimeric Live Attenuated Vaccine: Tetravalent Chimeric Vaccine; Monovalent Chimeric Vaccine
3) By Inactivated Vaccine: Whole Virus Inactivated Vaccine; Split Virus Vaccine
4) By Subunit Vaccine: Recombinant Protein Vaccine; Peptide-Based Vaccine
5) By Nucleic Acid Based Vaccine: DNA Vaccine; mRNA Vaccine
Companies Mentioned: Merck & Co. Inc.; Sanofi Pasteur Limited; GlaxoSmithKline plc; Takeda Pharmaceutical Company; Sun Pharmaceutical Industries Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r31776

1. Executive Summary

2. Dengue Vaccine Market Characteristics

3. Dengue Vaccine Market Trends And Strategies

4. Dengue Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Dengue Vaccine Growth Analysis And Strategic Analysis Framework

5.1. Global Dengue Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Dengue Vaccine Market Growth Rate Analysis
5.4. Global Dengue Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Dengue Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Dengue Vaccine Total Addressable Market (TAM)

6. Dengue Vaccine Market Segmentation

6.1. Global Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Live Attenuated Vaccine
Chimeric Live Attenuated Vaccine
Inactivated Vaccine
Subunit Vaccine
Nucleic Acid Based Vaccine
6.2. Global Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Phase I
Phase II
Phase III
6.3. Global Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diuretic
Anti-Allergic
Blood Thinners
Other Treatments
6.4. Global Dengue Vaccine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Routes Of Administration
6.5. Global Dengue Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Government Institutes
Non-Governmental Organizations
Other End-Users
6.6. Global Dengue Vaccine Market, Sub-Segmentation Of Live Attenuated Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single Strain
Multi-Strain
6.7. Global Dengue Vaccine Market, Sub-Segmentation Of Chimeric Live Attenuated Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tetravalent Chimeric Vaccine
Monovalent Chimeric Vaccine
6.8. Global Dengue Vaccine Market, Sub-Segmentation Of Inactivated Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Whole Virus Inactivated Vaccine
Split Virus Vaccine
6.9. Global Dengue Vaccine Market, Sub-Segmentation Of Subunit Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant Protein Vaccine
Peptide-Based Vaccine
6.10. Global Dengue Vaccine Market, Sub-Segmentation Of Nucleic Acid Based Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
DNA Vaccine
mRNA Vaccine

7. Dengue Vaccine Market Regional And Country Analysis

7.1. Global Dengue Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Dengue Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Dengue Vaccine Market

8.1. Asia-Pacific Dengue Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Dengue Vaccine Market

9.1. China Dengue Vaccine Market Overview
9.2. China Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Dengue Vaccine Market

10.1. India Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Dengue Vaccine Market

11.1. Japan Dengue Vaccine Market Overview
11.2. Japan Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Dengue Vaccine Market

12.1. Australia Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Dengue Vaccine Market

13.1. Indonesia Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Dengue Vaccine Market

14.1. South Korea Dengue Vaccine Market Overview
14.2. South Korea Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Dengue Vaccine Market

15.1. Western Europe Dengue Vaccine Market Overview
15.2. Western Europe Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Dengue Vaccine Market

16.1. UK Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Dengue Vaccine Market

17.1. Germany Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Dengue Vaccine Market

18.1. France Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Dengue Vaccine Market

19.1. Italy Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Dengue Vaccine Market

20.1. Spain Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Dengue Vaccine Market

21.1. Eastern Europe Dengue Vaccine Market Overview
21.2. Eastern Europe Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Dengue Vaccine Market

22.1. Russia Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Dengue Vaccine Market

23.1. North America Dengue Vaccine Market Overview
23.2. North America Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Dengue Vaccine Market

24.1. USA Dengue Vaccine Market Overview
24.2. USA Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Dengue Vaccine Market

25.1. Canada Dengue Vaccine Market Overview
25.2. Canada Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Dengue Vaccine Market

26.1. South America Dengue Vaccine Market Overview
26.2. South America Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Dengue Vaccine Market

27.1. Brazil Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Dengue Vaccine Market

28.1. Middle East Dengue Vaccine Market Overview
28.2. Middle East Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Dengue Vaccine Market

29.1. Africa Dengue Vaccine Market Overview
29.2. Africa Dengue Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Dengue Vaccine Market, Segmentation By Vaccine Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Dengue Vaccine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Dengue Vaccine Market Competitive Landscape And Company Profiles

30.1. Dengue Vaccine Market Competitive Landscape
30.2. Dengue Vaccine Market Company Profiles
- 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Sanofi Pasteur Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Takeda Pharmaceutical Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Dengue Vaccine Market Other Major And Innovative Companies

31.1. Biological E. Limited
31.2. Saint Louis University
31.3. Indian Immunologicals Limited
31.4. Serum Institute of India Pvt. Ltd.
31.5. Bavarian Nordic
31.6. Instituto Butantan
31.7. Bharat Biotech Ltd.
31.8. Panacea Biotec Limited
31.9. SABIN Vaccine Institute
31.10. Medigen Vaccine Biologics Corporation
31.11. Emergex Vaccines Holding Ltd.
31.12. BioNet-Asia Co. Ltd.
31.13. Codagenix Inc.
31.14. KM Biologics Co. Ltd.
31.15. Chula Vaccine Research Center

32. Global Dengue Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dengue Vaccine Market

34. Recent Developments In The Dengue Vaccine Market

35. Dengue Vaccine Market High Potential Countries, Segments and Strategies

35.1 Dengue Vaccine Market In 2029 - Countries Offering Most New Opportunities
35.2 Dengue Vaccine Market In 2029 - Segments Offering Most New Opportunities
35.3 Dengue Vaccine Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ